http://alnylam.com/Global/Media_Library.php Podcasts from Alnylam Pharmaceuticals Alnylam Pharmaceuticals Alnylam.com RSS en-us http://alnylam.com/Files/Podcasts/Icon/ALNY-podcast-petunia_600.jpg http://alnylam.com Copyright Tue, Oct 20 2009 12:01:01 Tue, Oct 20 2009 12:01:01 Alnylam RNAi Roundtable Series. The goal of the roundtable is to provide our listeners with an in-depth discussion around key topics relating to Alnylam and the development of RNAi therapeutics. A copy of the presentation slides can be found in our News and Events section on Alnylam.com under our events calendar. Copyright Fri, Jul 31 2009 12:01:01 Fri, Jul 31 2009 12:01:01 Our heads of clinical research discuss Alnylam the recent advancement of the ALN-VSP program, an RNAi Therapeutic for the Treatment of Liver Cancers, into human clinical trials. Copyright Thu, Jul 30 2009 12:01:01 Thu, Jul 30 2009 12:01:01 Dr. Sharp discusses the field of RNAi and Alnylam. Copyright Thu, Apr 23 2009 12:01:01 Thu, Apr 23 2009 12:01:01 The program leader for Alnylam's hypercholesterolemia program describes the recent PNAS publication that demonstrated for the first time an RNAi therapeutic targeting the PCSK9 gene has significantly decreased LDL cholesterol in three pre-clinical animal models - mouse, rat and non-human primate. Copyright Tue, Oct 7 2008 12:01:01 Tue, Oct 7 2008 12:01:01 Jason Rhodes, VP of Business Development provides an overview of Alnylam's numerous partnerships, the value that the bring to the company as well as the company's overall business development strategy Copyright Tue, Oct 7 2008 12:01:01 Tue, Oct 7 2008 12:01:01 Alnylam's CEO, John Maraganore, provides insight into company's unique innovative culture. Copyright Tue, Oct 7 2008 12:01:01 Tue, Oct 7 2008 12:01:01 Alnylam's President and COO discusses the company's RNAi 2010 plan, an initiative that was created to provide color on Alnylam's scientific, clinical and business initiatives developing beyond 2008 Copyright Tue, Oct 7 2008 12:01:01 Tue, Oct 7 2008 12:01:01 Dr. Akshay Vaishnaw, VP of Clinical provides a general overview on the progress of Alnylam's lead program, ALN-RSV01, including the GEMINI data, lung transplant trial initiation and the timeline Copyright Tue, Oct 7 2008 12:01:01 Tue, Oct 7 2008 12:01:01 One of the lead authors discusses new research published in Nature that documents the design and synthesis of a new class of lipid-based molecules called "lipidoids", which were used to form novel nanoparticle formulations for systemic delivery of RNAi therapeutics. Copyright Tue, Oct 7 2008 12:01:01 Tue, Oct 7 2008 12:01:01